TBPH Theravance Biopharma Inc

Price (delayed)

$18.42

Market cap

$1.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.31

Enterprise value

$1.76B

Sector: Healthcare
Industry: Biotechnology

Highlights

Theravance Biopharma's EPS has increased by 3.4% QoQ
The company's quick ratio fell by 43% YoY but it rose by 4.1% QoQ
TBPH's equity has dropped by 136% year-on-year and by 23% since the previous quarter
TBPH's revenue is down by 25% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of TBPH
Market
Shares outstanding
65.28M
Market cap
$1.2B
Enterprise value
$1.76B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
17.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.56
Earnings
Revenue
$66.25M
EBIT
-$235.67M
EBITDA
-$226.13M
Free cash flow
-$272.53M
Per share
EPS
-$4.31
Free cash flow per share
-$4.23
Book value per share
-$5.8
Revenue per share
$1.03
TBVPS
$5.82
Balance sheet
Total assets
$375.11M
Total liabilities
$748.33M
Debt
$672.32M
Equity
-$373.22M
Working capital
$206.58M
Liquidity
Debt to equity
-1.8
Current ratio
3.39
Quick ratio
3.06
Net debt/EBITDA
-2.47
Margins
EBITDA margin
-341.3%
Gross margin
100%
Net margin
-414.5%
Operating margin
-466.7%
Efficiency
Return on assets
-57.2%
Return on equity
N/A
Return on invested capital
-25%
Return on capital employed
-81.7%
Return on sales
-355.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TBPH stock price

How has the Theravance Biopharma stock price performed over time
Intraday
-1.6%
1 week
-4.01%
1 month
-15.15%
1 year
-32.8%
YTD
3.66%
QTD
-9.75%

Financial performance

How have Theravance Biopharma's revenue and profit performed over time
Revenue
$66.25M
Gross profit
$66.25M
Operating income
-$309.17M
Net income
-$274.64M
Gross margin
100%
Net margin
-414.5%
Theravance Biopharma's operating margin has shrunk by 64% YoY and by 13% QoQ
Theravance Biopharma's net margin has decreased by 48% YoY and by 7% QoQ
TBPH's revenue is down by 25% year-on-year and by 8% since the previous quarter
The gross profit has contracted by 25% YoY and by 8% from the previous quarter

Growth

What is Theravance Biopharma's growth rate over time

Valuation

What is Theravance Biopharma stock price valuation
P/E
N/A
P/B
N/A
P/S
17.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.56
Theravance Biopharma's EPS has increased by 3.4% QoQ
TBPH's equity has dropped by 136% year-on-year and by 23% since the previous quarter
The P/S is 50% lower than the 5-year quarterly average of 36.2 but 12% higher than the last 4 quarters average of 16.0
TBPH's revenue is down by 25% year-on-year and by 8% since the previous quarter

Efficiency

How efficient is Theravance Biopharma business performance
Theravance Biopharma's return on sales has decreased by 41% YoY and by 6% QoQ
The ROIC has grown by 15% YoY and by 2.7% from the previous quarter
The company's return on assets fell by 13% YoY and by 11% QoQ

Dividends

What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TBPH.

Financial health

How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 50% less than its total liabilities
The company's quick ratio fell by 43% YoY but it rose by 4.1% QoQ
Theravance Biopharma's total assets has decreased by 38% YoY and by 20% from the previous quarter
TBPH's equity has dropped by 136% year-on-year and by 23% since the previous quarter
The debt to equity has soared by 57% YoY and by 19% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.